Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II olanzapine + dexamethasone + palonosetron for prevention of highly emetogenic chemotherapy-induced nausea and vomiting
ChiCTR1800017724Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olanzapine, dexamethasone and palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Chinese PLA General Hospital. Primary endpoint: Complete response rate of nausea and vomiting. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
olanzapinedexamethasonepalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR1800017724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017724.